ArticleCancer medicine2014

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.

Aaron D Schenone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.